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Although the recent SARS coronavirus (SARS-CoV) that appeared in 2002 has now been contained, the possibility of re-emergence of
SARS-CoV remains. Due to the threat of re-emergence, the overall fatality rate of ¨10%, and the rapid dispersion of the virus via
international travel, viable vaccine candidates providing protection from SARS are clearly needed. We developed an attenuated VSV
recombinant (VSV-S) expressing the SARS coronavirus (SARS-CoV) spike (S) protein. In cells infected with this recombinant, S protein was
synthesized, glycosylated at approximately 17 Asn residues, and transported via the Golgi to the cell surface. Mice vaccinated with VSV-S
developed SARS-neutralizing antibody and were able to control a challenge with SARS-CoV performed at 1 month or 4 months after a single
vaccination. We also demonstrated, by passive antibody transfer, that the antibody response induced by the vaccine was sufficient for
controlling SARS-CoV infection. A VSV-vectored SARS vaccine could have significant advantages over other SARS vaccine candidates
described to date.
D 2005 Published by Elsevier Inc.Keywords: Intranasal; Neutralizing antibodies; Protective immunity; SpikeIn the fall of 2002 an emerging human disease termed
SARS (severe acute respiratory syndrome) drew global
attention. The disease was characterized as an atypical
pneumonia accompanied by high fever. According the
World Health Organization, there were 8096 cases of
SARS, 21% of which were in health care workers.
Approximately 10% of the infected individuals died as a
result of the illness, and the death rate exceeded 50% for
those over 60 years old (http://www.who.int/csr/sars/en/
WHOconsensus.pdf and Peiris et al., 2004). The causative
agent was identified as a coronavirus (Drosten et al., 2003;
Ksiazek et al., 2003), a positive-stranded enveloped RNA
virus, and the 29.7-kb genome sequence was determined0042-6822/$ - see front matter D 2005 Published by Elsevier Inc.
doi:10.1016/j.virol.2005.06.016
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E-mail address: john.rose@yale.edu (J.K. Rose).rapidly. Like other coronaviruses, the SARS coronavirus
(SARS-CoV) has 6 major open reading frames, two
encoding the polymerase, and four encoding the structural
proteins spike (S), membrane, envelope, and nucleocapsid
(Marra et al., 2003; Rota et al., 2003). The SARS S protein
is a type I transmembrane glycoprotein. It is responsible for
viral binding to host cellular receptors, identified as
angiotensin converting enzyme 2 (Li et al., 2003) and
CD209L (Jeffers et al., 2004), followed by viral fusion to
host cells (Bosch et al., 2004; Liu et al., 2004; Yuan et al.,
2004). Immunization with the S proteins of other corona-
viruses (mouse hepatitis virus [MHV], transmissible gastro-
enteritis virus [TGEV], and infectious bronchitis virus
[IBV]) generates protective immunity against these viruses
in various animal models (De Diego et al., 1992; Ignjatovic
and Galli, 1994; Wesseling et al., 1993). Expression of the S
protein of SARS-CoV from either in vitro expression05) 174 – 182
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to generate protection against SARS-CoV infection in
animal models (Bisht et al., 2004; Bukreyev et al., 2004;
Chen et al., 2005; Gao et al., 2003; Yang et al., 2004).
The spread of SARS was curtailed by public health
measures, and the outbreak was successfully contained in
July 2003. Although several animals are susceptible to
SARS-CoV infection, the source of the outbreak and host
reservoir are uncertain (Guan et al., 2003). The possibility of
a re-emergence still exists, and in such an event, a SARS
vaccine would be valuable, especially to protect the most
vulnerable groups, the elderly and health care workers.
In this study, an experimental vesicular stomatitis virus
(VSV)-based SARS vaccine was developed and tested.
VSV is a negative strand RNA virus with a non-segmented
genome that encodes five structural proteins, nucleocapsid
(N), phosphoprotein (P), matrix (M), glycoprotein (G), and
an RNA-dependent RNA polymerase (L). VSV can elicit
strong humoral and cellular immune responses in a variety
of animals, and VSV-based vaccines have been shown to
confer immunity in animal models of respiratory syncytial
virus (Kahn et al., 2001), influenza virus (Roberts et al.,
1998), SHIV/AIDS (Rose et al., 2001), measles virus
(Schlereth et al., 2000), and human papilloma virus (Roberts
et al., 2004). VSV has significant advantages over many
other vaccine vectors. It has a relatively small RNA genome
but can accommodate insertion of large foreign genes. It
replicates exclusively in the cytoplasm via RNA intermedi-
ates only and does not undergo recombination. VSV
seropositivity is also extremely low in the general popula-
tion (Rose and Whitt, 2001). Recombinant VSV generated
by the plasmid DNA system employed here have been
shown to be less pathogenic (attenuated) when compared
with naturally occurring strains of VSV (Roberts et al.,
1998) and cause no disease symptoms in non-human
primates (Rose et al., 2001) when given by intranasal, oral,
or intramuscular routes. In the present study, we developed a
recombinant, attenuated VSV expressing the SARS-CoV S
protein and tested it as a SARS vaccine in a mouse model
(Subbarao et al., 2004). In this model, SARS-CoV replicates
to high titers in the respiratory tract, allowing protection
from SARS infection to be assayed readily in vaccinated
animals following SARS-CoV challenge.Fig. 1. VSV recombinant expressing the SARS-CoV S protein. (A) The
diagram illustrates the genome of the VSV-S recombinant expressing the S
gene and shows the terminal coding and flanking VSV transcription start
and stop signals. (B) BHK-21 cells were infected with wt VSV (lanes 1
and 2) or VSV-S (lanes 3 and 4), labeled with [35S]-methionine, and
lysates were analyzed by SDS–PAGE without (lanes 1 and 3) or with
immunoprecipitation with anti-S antibody (lanes 2 and 4). (C) Immuno-
precipitated S was left undigested (lane 1), digested with PNGase F (lane 2),
or Endo H (lane 3).Results
Construction and characterization of a VSV recombinant
(VSV-S) expressing SARS-CoV S protein
To determine if the SARS-CoV S protein could be
expressed from a VSV recombinant, we first generated a
cDNA clone of the SARS S gene by reverse transcription
and PCR amplification of RNA purified from SARS-CoV-
infected cells. We next constructed a plasmid with the
SARS-CoV S coding sequence inserted between the VSV Gand VSV L genes (Fig. 1A). Appropriate VSV transcription
start and stop sites flanked the S gene. We recovered a
recombinant VSV (designated VSV-S) from this plasmid
using published methods (Lawson et al., 1995). To
determine if the recombinant virus expressed the SARS S
protein, we infected BHK cells with the recovered virus or
with wt VSV and metabolically labeled cells for 1 h with
[35S]-methionine. Lysates of radiolabeled cells were then
analyzed by SDS–PAGE. Since VSV shuts off host protein
synthesis, wt VSV-infected cells express predominantly the
five viral proteins L, G, N, P, and M. VSV-S-infected cells
expressed the five VSV proteins (Fig. 1B), and also a
protein of the expected size for S (calculated as ¨197 kDa
assuming N-glycosylation at all 23 potential sites). To verify
the identity of the S protein, S was immunoprecipitated from
the cell lysates using a rabbit polyclonal antibody to the S
cytoplasmic domain. The immunoprecipitated protein
S.U. Kapadia et al. / Virology 340 (2005) 174–182176appeared as two bands (Fig. 1C, lane 1), potentially
representing two different glycosylation states of S. To
examine this possibility we treated the protein with PNGase
F (Fig. 1C, lane 2), which cleaves all N-linked glycans.
PNGase F-digestion yielded a single band of approximately
156 kDa, confirming that variable glycosylation states of the
S protein were responsible for the observed size hetero-
geneity. Digestion of immunoprecipitated S protein with
Endo H, an endoglycosidase that cleaves only unprocessed
or partially processed glycans from proteins, yielded two
bands (Fig. 1C, lane 3). The Endo-H-resistant band of
original size accounted for ¨15% of total S protein. The
lower band, representing protein which had not yet under-
gone processing of its carbohydrate side chains, accounted
for ¨85% of total S protein. In a pulse-chase experiment
with a 20-min pulse labeling, we observed that 50% of S
expressed by VSV was Endo H resistant within 30 min after
the chase was begun (data not shown). From these experi-
ments, we concluded that the S protein is transported
through the exocytic pathway at least as far as the Golgi
apparatus where Endo H resistance is acquired.
To determine if the S protein was transported from the
Golgi to the cell surface, we examined VSV-S-infected cells
using indirect immunofluorescence microscopy. BHK-21
cells were infected with VSV-S or wt VSV, fixed, and thenFig. 2. SARS-CoV S protein is expressed on the surface of VSV-S-infected cells.
Cells were fixed and stained for SARS S as described in Materials and methods. T
Microphot-FX microscope using a 60 objective.incubated with serum from a person who had recovered
from SARS-CoV infection. A secondary, Alexa Fluor 488-
conjugated anti-human antibody was used for visualization
with fluorescence microscopy. We found that the SARS S
protein was clearly expressed on the cell surface as indicated
by the strong fluorescent signal visible in VSV-S-but not wt
VSV-infected cells (Fig. 2).
Immunization with VSV-S elicits humoral immunity
Initially we immunized four groups of eight mice with
either wt VSV, VSV-S, or SARS-CoV. Four weeks later,
serum was collected from each mouse. To determine if the
VSV and VSV-S inoculations were effective, we performed
an assay to measure VSV-neutralizing antibodies. Pooled
sera from mice infected with wt VSVor VSV-S had a VSV-
neutralizing antibody titer of 1:2560, while mice infected
with SARS-CoV did not have any detectable VSV-
neutralizing antibody.
We then examined the individual serum samples for
neutralizing antibodies to SARS-CoV (Table 1). Infection of
mice with VSV-S generated a stronger neutralizing antibody
response (average SARS-neutralizing titer of 1:32) to
SARS-CoV than did infection with SARS-CoV (average
SARS-neutralizing titer of 1:12). Sera from control miceBHK-21 cells were infected with VSV-S (A and B) or wt VSV (C and D).
he fluorescence (left) and DIC (right) images were generated with a Nikon
Table 1
Neutralizing antibody titers to SARS-CoV
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ing antibody titers to SARS-CoV.
Immunization with VSV-S protects against SARS-CoV
infection
Mice inoculated intranasally with SARS-CoV do not
show any clinical symptoms of infection; however, the virus
replicates to high titers in the lungs and nasal turbinates
(NTs). SARS-CoV replication in respiratory tissues peaks
by 2 days post-infection and virus is cleared within a week
(Subbarao et al., 2004). We examined SARS-CoV repli-Fig. 3. Protection from SARS-CoV infection in immunized mice. Balb/c mice were
challenged 4 weeks later with 105 TCID50 SARS-CoV. Two days later, lungs an
Additional mice were challenged 4 months after immunization with wt VSV, VS
turbinates were collected and viral titers were determined (B). Limits of dete
log10TCID50/g tissue in 5% nasal turbinate homogenates.cation in vaccinated and control animals to evaluate the
effectiveness of the VSV-S vaccine in protecting against
SARS-CoV infection.
Three groups of four mice each were immunized with
either wt VSV, VSV-S, or SARS-CoV. Four weeks later the
mice were challenged with SARS-CoV, and 2 days after the
challenge, the lungs and nasal turbinates were collected,
and the corresponding viral titers were determined (Fig.
3A). Control mice, immunized with wt VSV, had high
SARS viral titers in both lungs and nasal turbinates
following SARS-CoV challenge. In contrast, mice immu-
nized with VSV-S or SARS-CoV were completely pro-
tected and controlled the SARS-CoV challenge as indicated
by SARS-CoV titers at or below the detection limits in both
the lungs and nasal turbinates. These data indicate that
vaccination with VSV-S is as effective as a primary
infection with SARS-CoV in preventing subsequent
SARS-CoV infections.
To determine if VSV-S vaccination could provide
sustained protection from SARS-CoV infection, a similar
experiment was carried out with a 4-month interval between
immunizations and challenge (Fig. 3B). Two days after
challenge, SARS-CoV titers in the lungs of VSV-S immu-
nized mice were at the limit of detection (1 of 4 mice) orinoculated intranasally with wt VSV, VSV-S, or SARS-CoV. The mice were
d nasal turbinates were collected, and the viral titers were determined (A).
V-SARS S, and SARS-CoV. Two days after the challenge, lungs and nasal
ction were 1.5 log10TCID50/g tissue in 10% lung homogenates and 1.8
Fig. 4. Inhibition of SARS-CoV replication by transfer of serum from immunized mice. Sera from uninfected mice or mice immunized with VSV-S, SARS-
CoV (diluted 1:10 in PBS), or wt VSV was injected into naı¨ve mice. Serum was then collected from mice to measure SARS-CoV-neutralizing antibody titer.
(The limit of detection was a reciprocal dilution of 8.) The mice were then infected with SARS-CoV, and 2 days later the lungs were harvested to measure
SARS-CoV titer. The limit of detection was 1.5 log10TCID50/g.
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SARS-CoV immunized mice was slightly above the limit of
detection (1 of 4 mice) or undetectable (3 of 4 mice). Viral
titers in the nasal turbinates were slightly above the limit of
detection for both VSV-S (3 of 4 mice)- and SARS-CoV
(2 of 4 mice)-immunized mice. The mean SARS viral
titers in nasal turbinates of both VSV-S- and SARS-CoV-
inoculated mice were nearly 10,000-fold lower than the
viral titers in nasal turbinates from wt VSV-immunized
mice. These findings demonstrate that VSV-S vaccination
provides sustained protection from SARS-CoV challenge
and may provide protective immunity equal to or better
than primary SARS-CoV infection.
Serum from mice immunized with VSV-S can confer passive
protection
VSV infection can elicit strong humoral and cellular
immune responses. To determine if antibody alone could
provide protection against SARS-CoV infection, serum
from wt VSV-, VSV-S-, or SARS-CoV-infected mice was
administered intraperitoneally into naı¨ve mice (Fig. 4). Mice
were bled 24 h after administration of antisera and SARS-
CoV-neutralizing antibody titers were measured. Mice were
subsequently challenged with SARS-CoV, and 2 days later
lungs were collected and SARS-CoV titers were deter-
mined. SARS-CoV-neutralizing antibody titers were detect-
able in the groups of mice that received VSV-S antisera and
SARS-CoV antisera (diluted 1:10). Only these mice were
able to protect against SARS-CoV infection upon challenge.
Mice receiving wt VSV antisera or normal mouse sera did
not have measurable neutralizing antibodies to SARS-CoV,
nor were they protected from SARS-CoV infection upon
challenge. These results demonstrate that VSV-S can elicit a
strong antibody response that is sufficient for controlling
SARS-CoV infection.Discussion
In this study we used an attenuated VSV vector to
express the SARS-CoV S protein gene. Because both
SARS-CoV and VSV replicate in the cytoplasm of infected
cells, we anticipated efficient expression of SARS-CoV S
protein by a recombinant VSV without problems associated
with nuclear transcription, including mRNA modification
and mRNA export from the nucleus. The level of S protein
expression obtained from the VSV-S recombinant was
clearly sufficient to generate long-term protective immunity
to SARS-CoV in this animal model.
The levels of SARS-CoV-neutralizing antibody titers
following VSV-S immunization were equal to or better than
those elicited following primary infection with SARS-CoV.
Although passive transfer of immune sera demonstrated that
antibody induced by either VSV-S or SARS-CoV inocu-
lations is sufficient to prevent SARS-CoV infection, cellular
immune responses may also contribute to protection.
Similarly, it has been shown with other coronaviruses, such
as mouse hepatitis virus type 3, that antibody-mediated
immunity is sufficient for protection (Pope et al., 1996).
Furthermore, the complete protection from SARS viral
replication in the lower respiratory tissues of VSV-S-immu-
nized mice observed when challenge was administered 4
months post-immunization suggests that prolonged protec-
tion may be provided from a single immunization with
VSV-S. Ours is the first study to show such long-term
protection after immunization with an experimental SARS-
CoV vaccine. In previous studies on vaccination of mice with
VSV expressing an influenza hemagglutinin, we found that
protective influenza-neutralizing antibody titers were very
long-lived, declining only 2- to 4-fold over the course ofmore
than one year (Roberts and Rose, unpublished data).
Our VSV-based SARS vaccine could have significant
advantages over previously described SARS vaccines (Bisht
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al., 2003; Yang et al., 2004). Pre-existing immunity to VSV
is rare in the human population. Effectiveness of other
vaccine candidates based on adenovirus or parainfluenza
virus could be limited by a high prevalence of pre-existing
immunity to the vectors in the human population. Vaccines
based on modified vaccinia Ankara (MVA) could face the
same problem because the parental vaccinia virus has been
used worldwide as the smallpox vaccine, and there is
extensive immunity to vaccinia, especially in the older
population most susceptible to SARS (Crotty et al., 2003).
DNA vaccines have been effective, especially in small
animal models; however, efficacy in humans has yet to be
demonstrated. VSV has the additional advantages of
growing to very high titers in cell lines such as Vero that
are approved for human vaccine production. VSV is also
effective at very low doses (Roberts et al., 1998, 1999) and
is effective as an intranasal vaccine (Egan et al., 2004).
Inactivated SARS-CoV itself has also been shown to
elicit an immune response (He et al., 2004; Qu et al., 2005;
Takasuka et al., 2004; Tang et al., 2004; Xiong et al., 2004;
Zhang et al., 2004); however, the production of such a
vaccine would carry the inherent risks of exposure to SARS-
CoV from handling large volumes of infectious material that
could result in accidental infection and secondary spread.
Additionally, there might be concerns of proper and
complete inactivation of the virus.
The SARS-CoV S protein expressed by VSV was
estimated from gel mobility to be approximately 200 kDa
and was converted to about 156 kDa upon the removal of all
N-linked glycans. Based on this calculation, we estimate
that at least 17 of the 23 potential N-linked glycosylation
sites are used (assuming 2.5 kDa per N-linked glycan). We
also demonstrated that S expressed from the VSV recombi-
nant moves to the Golgi apparatus where it acquires Endo H
resistance. About 15% of S expressed during a 1-h labeling
period contained Endo-H-resistant glycans. In a pulse-chase
experiment with a 20-min pulse labeling, we observed that
50% of S expressed by VSV was Endo H resistant within 30
min after the chase was begun (data not shown). Finally, we
readily observed S protein on the cell surface. Our results
indicate that S protein moves efficiently through the
exocytic pathway when it is expressed in the absence of
other SARS virus proteins. Exposure of S protein on the cell
surface of infected cells is likely to be important in the
induction of a neutralizing antibody response.
Other coronavirus vaccines, including those for MHV,
IBV, and TGEV, have been effective in controlling infection.
In contrast, vaccine against feline infectious peritonitis virus
using the S protein of that virus as an antigen enhanced
disease in cats (Vennema et al., 1990). No such enhancement
of infection was observed in the present mouse model in this
and previous studies. However, since SARS-CoV does not
cause a disease in mice, this model may not reveal such
effects. Mild to moderate hepatic lesions have been observed
in a single set of experiments where ferrets were vaccinatedwith MVA, MVA-SAR-S, or MVA-SARS-N and challenged
with SARS-CoV (Czub et al., 2005; Weingartl et al., 2004).
The significance of these lesions is unclear since they occur
in MVA vaccinated, SARS-CoV-challenged animals, as well
as unvaccinated (PBS controls) SARS-CoV challenged
animals. Although two of three ferrets receiving MVA-
SAR-S vaccine have slightly larger lesions following SARS-
CoV challenge, it is difficult to ascertain whether hepatic
disease is enhanced or just variable. Furthermore, SARS-
CoV disease is primarily a respiratory disease, and the lesions
in the liver may have little or no relevance to SARS-CoV
disease. These observations may therefore be isolated to the
use of this vector or this animal model or the specific
combination. The potential for SARS-CoV-enhanced disease
in previously vaccinated or SARS-exposed animals requires
further studies in models that more closely mimic the human
disease.Materials and methods
Plasmid construction and recombinant VSV recovery
The SARS-CoV S gene was amplified fromRNA of virus-
infected cells (provided by Dr. William Bellini, CDC) by
reverse transcription-PCR using Superscript One-Step RT-
PCR for Long Templates (Invitrogen, Carlsbad, CA). The
following primers were used in the RT-PCR: 5V-GATC-
GATCCTCGAGAACATGTTTATTTTCTTAATTATTTC-3V
and 5V-CGATCCCCCCGGGCTAGCTTATGTGTAATG-
TAATTTGACACCC. The PCR product was digested with
XhoI and NheI and ligated into pVSVXN2 (Schnell et al.,
1996), also digested with the same enzymes. The resulting
clone, pVSV-SARS S, was sequenced. The S gene sequence
matched the published sequence (GenBank accession no.
AY278741) with the exception of a silent mutation at
nucleotide 1173 which was G instead of A.
Recombinant virus was recovered as previously described
(Lawson et al., 1995). Briefly, BHK-21 cells were infected
with vTF7-3 (Fuerst et al., 1986) for 1 h and then transfected
with pVSV-SARS S and support plasmids (pBS-N, pBS-M,
pBS-G, and pBS-L) for 3 h. Two days after the transfection,
the media were transferred onto fresh BHK-21 cells. The
media were collected after 2 days. A stock of VSV-S from a
single plaque was grown on BHK-21. Recombinant wild-
type (wt) VSV (Lawson et al., 1995) was also grown on
BHK-21.
SARS S antibody
In order to detect SARS-CoV S protein, antibodies
directed to the c-terminal domain were produced. Rabbits
were immunized and boosted with the peptide KFDEDD-
SEPVLKGVKLHYT coupled to KLH. Serum was collected
and affinity purified (Pocono Rabbit Farm and Laboratory
Inc., Canadensis, PA).
S.U. Kapadia et al. / Virology 340 (2005) 174–182180Metabolic labeling, immunoprecipitation, and SDS–PAGE
BHK-21 cells were infected with either VSV-SARS S or
wt VSVat a multiplicity of infection (MOI) of 10. After 5 h,
the cells were washed twice with methionine-free Dulbec-
co’s modified Eagle’s medium (DMEM) and incubated with
DMEM containing 100 ACi of [35S]-methionine for 1 h.
Cells were washed with phosphate-buffered saline (PBS)
and then lysed with a detergent solution (1% Nonidet P-40,
0.4% deoxycholate, 50 mM Tris–HCl [pH 8], 62.5 mM
EDTA). Protein samples were analyzed by SDS–10%
PAGE.
SARS S was immunoprecipitated from lysate with the S-
tail antiserum at a dilution of 1:100 at 4 -C overnight.
Protein A-Sepharose (Zymed Laboratories Inc., San Fran-
cisco, CA) was added and allowed to incubate for 1 h at
room temperature. The Sepharose was washed with HNTG
buffer (50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 10% glycerol, 0.1% Triton X-100).
The immunoprecipitates were treated with Endoglycosi-
dase (Endo) H and peptide N-Glycosidase (PNGase) F
(New England Biolabs, Beverly, MA) according to manu-
facturer’s instructions.
Immunofluorescence microscopy
BHK-21 cells seeded onto glass coverslips were infected
with either VSV-S or wt VSV at an MOI of 10. 6 h after
infection, the cells were washed with PBS and fixed with 3%
paraformaldehyde. The cells were then washed with PBS–
glycine (10 mM). Coverslips were incubated with a 1:200
dilution serum from a person who had recovered from SARS
(provided by Dr. William Bellini, CDC). The coverslips were
washed with PBS–glycine and incubated with a 1:500
dilution of Alexa Fluor 488 goat anti human IgG (Molecular
Probes, Eugene, OR). Coverslips were washed and mounted
on slides using glycerol containing 0.1 M n-propylgallate.
Cells were observed with Nikon Microphot-FX epi-fluores-
cence microscope using a 60 objective.
Animal challenge protocol
Three groups of eight BABL/c mice were inoculated
intranasally (i.n.) with either 1.6  104 pfu of wt VSV,
1.4  104 pfu of VSV-SARS S, or 105 TCID50 of SARS-
CoV. Twenty-eight days after the immunization, serum
was collected from all mice to measure neutralizing
antibody titers. Four mice from each group were then
challenged i.n. with 104 TCID50 SARS-CoV as previously
described (Subbarao et al., 2004). Two days later, lungs
and nasal turbinates of the mice were collected to
determine viral titers (Subbarao et al., 2004). The
remaining four mice were challenged 4 months post-
immunization. Lungs and nasal turbinates were collected
2 days after the challenge, and viral titers were
determined (Subbarao et al., 2004).Neutralizing antibody titers
VSV-neutralizing antibody titers were measured by
determining the highest dilution of serum that could
prevent killing of a monolayer of BHK-21 cells by VSV
(Rose et al., 2001). SARS-CoV-neutralizing antibody titers
were determined by evaluating the serum dilution at which
the cytopathic effects (CPE) of SARS-CoV were inhibited
in half of the wells containing Vero E6 monolayer
(Subbarao et al., 2004).
Passive protection study
Sera from mice immunized with wt VSV, VSV-S, and
SARS-CoV were collected and heat inactivated. Two groups
of six mice were injected intraperitoneally (i.p.) with 500 Al
of wt VSVor VSV-S immune sera. Two additional groups of
six mice were also injected i.p. with 500 Al of SARS
immune sera diluted 1:10 in PBS or sera of naı¨ve mice.
Serum was collected from each mouse to determine
neutralizing antibody titers against SARS-CoV (Subbarao
et al., 2004). Mice were then inoculated i.n. with 105
TCID50 of SARS-CoV. Two days later, the lungs were
collected from each mouse, and viral titer was determined as
described above.Acknowledgments
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